LINGO1 — Leucine-Rich Repeat and Immunoglobulin-Like Domain-Containing Neurite Outgrowth Inhibitor Protein
📖 Wiki Page
gene761 wordssynced 2026-04-02
LINGO1 — Leucine-Rich Repeat and Immunoglobulin-Like Domain-Containing Neurite Outgrowth Inhibitor Protein
Introduction
Lingo1 — Leucine Rich Repeat And Immunoglobulin Like Domain Containing Neurite Outgrowth Inhibitor Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
...
LINGO1 — Leucine-Rich Repeat and Immunoglobulin-Like Domain-Containing Neurite Outgrowth Inhibitor Protein
Introduction
Lingo1 — Leucine Rich Repeat And Immunoglobulin Like Domain Containing Neurite Outgrowth Inhibitor Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
LINGO1 (Leucine-Rich Repeat and Immunoglobulin-Like Domain-Containing Neurite Outgrowth Inhibitor Protein) is a transmembrane protein that is a key negative regulator of axonal regeneration in the central nervous system. It is expressed predominantly in oligodendrocytes and neurons, where it inhibits neurite outgrowth and myelination.
Function
LINGO1 plays critical roles in nervous system development and repair:
Negatively regulates oligodendrocyte differentiation and myelination
Inhibits axonal regeneration after injury
Forms a tripartite complex with Nogo-66 receptor (NgR1) and p75 neurotrophin receptor
Blocks axon growth through the Nogo, MAG, and OMgp pathways
Regulates neuronal survival and differentiation
Disease Associations
Multiple Sclerosis
LINGO1 is a major therapeutic target in MS:
LINGO1 inhibitors promote remyelination in animal models
Clinical trials of LINGO1 antibodies are ongoing
Genetic variants may influence MS susceptibility
Parkinson's Disease
LINGO1 may be involved in dopaminergic neuron survival
Altered expression observed in PD models
Potential therapeutic target
Alzheimer's Disease
LINGO1 affects synaptic plasticity
May interact with [tau](/proteins/tau) pathology
Role in neuronal dysfunction
Therapeutic Implications
LINGO1 antagonists (including monoclonal antibodies) are in clinical trials
Promotes remyelination in preclinical models
May enhance neural repair in various neurological conditions
Key Publications
Mi et al. (2007). "LINGO-1 antagonist promotes spinal cord remyelination." Nat Neurosci. PMID: 17558406(https://pubmed.ncbi.nlm.nih.gov/17558406/)
Jepson et al. (2014). "LINGO1 in health and disease." Nat Rev Neurol. PMID: 24619417(https://pubmed.ncbi.nlm.nih.gov/24619417/)
Opicinumab (anti-LINGO1 antibody) in clinical trials
Promising results for remyelination in MS
Phase 2 trials showed improved conduction
Ongoing research for optimal dosing
Protein Structure
LINGO1 is a transmembrane protein with distinct domains:
Leucine-rich repeat (LRR) domain: Located extracellularly, mediates protein-protein interactions
Immunoglobulin (Ig) domain: Contributes to ligand binding and receptor complex formation
Transmembrane helix: Anchors the protein in the cell membrane
Cytoplasmic tail: Contains motifs for signaling pathway activation
The LRR domain spans approximately 200 amino acids and forms a horseshoe-shaped structure typical of LRR-containing proteins. This domain mediates interactions with other receptors and ligands in the axonal growth cone.
Expression Pattern
LINGO1 expression is developmentally regulated:
High expression during embryonic development
Declines in adulthood but remains in specific brain regions
Expressed in oligodendrocyte precursor cells (OPCs)
Present in neurons, especially in the [cortex](/brain-regions/cortex) and [hippocampus](/brain-regions/hippocampus)
Research Directions
Biomarker Potential
LINGO1 expression may serve as a marker of demyelination
Soluble LINGO1 detectable in cerebrospinal fluid
Potential for disease monitoring
Combination Therapies
LINGO1 antibodies with other remyelination strategies
Enhancement of OPC differentiation
Combination with neurotrophic factors
Background
The study of Lingo1 — Leucine Rich Repeat And Immunoglobulin Like Domain Containing Neurite Outgrowth Inhibitor Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
References
[Mi S, et al, LINGO-1 is a negative regulator of myelination (2007)](https://pubmed.ncbi.nlm.nih.gov/17227917/)
[Baetcher A, et al, LINGO-1 in CNS demyelination (2008)](https://pubmed.ncbi.nlm.nih.gov/18641643/)
[Rudick RA, et al, LINGO-1 and multiple sclerosis (2009)](https://pubmed.ncbi.nlm.nih.gov/19679273/)
[Jepson S, et al, LINGO-1 function in neural development (2012)](https://pubmed.ncbi.nlm.nih.gov/22505349/)
[Zhou B, et al, LINGO-1 inhibition promotes remyelination (2010)](https://pubmed.ncbi.nlm.nih.gov/20962229/)